EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mass balance study of [ 14 C]Netanasvir Phosphate in healthy Chinese participants

Chun-Yang Zhao iD, Gang-Yi Liu, Lin Qian, Yu-Lei Zhuang, Lin Luo, Ying-Jun Zhang, Hong-Ming Xie, Jing Zhu, Ming Li, Qian Chen, Yun Liu, Jing-Ying Jia iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)

DOI: 10.1128/aac.01655-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Chun-Yang Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antiviral Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Netanasvir Phosphate is a novel second-generation NS5A inhibitor used for the treatment of chronic hepatitis C virus (HCV) infection. This study investigated the absorption, distribution, metabolism, and excretion (ADME), and the metabolite profile of [¹⁴C]Netanasvir Phosphate. In a single-dose, open-label study, six healthy Chinese male volunteers received an oral dose of 100 mg/200 µCi of [¹⁴C]Netanasvir Phosphate under fed conditions. Blood, urine, and fecal samples were collected for up to 336 h post-dose. Total radioactivity was measured using oxidative combustion and liquid scintillation counting, and the parent drug and its metabolites were analyzed by validated liquid chromatography–tandem mass spectrometry and low-energy radiometric detection and mass spectrometry methods. The pharmacokinetic profile showed a median T max of 5.5 h and a mean terminal half-life of 30.6 ± 8.52 h. The average total recovery of radioactivity was 97.73% ± 1.90%, with feces accounting for 97.71% of the administered dose and urine only 0.02%, indicating that fecal excretion is the primary elimination pathway. The parent drug was the predominant circulating and excreted component, representing 93.89% of plasma radioactivity and 78.78% of the administered dose in feces. Only minor metabolites were detected, including demethylated and oxidized derivatives. The drug was well tolerated, with no serious adverse events (SAEs) or dose-limiting toxicities observed. This mass balance and metabolite profiling study provides essential evidence supporting the favorable pharmacokinetic characteristics and metabolic stability of [¹⁴C]Netanasvir Phosphate and offers a scientific foundation for further clinical development in HCV-infected populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsAdultHumansMaleYoung AdultAdministration, OralCarbon RadioisotopesFecesHealthy VolunteersTandem Mass SpectrometryEast Asian People

Stichwörter der Autor:innen

absorptiondistributionmass balancemetabolismmetabolitespharmacokineticssafety

Substanzen

Antiviral AgentsCarbon RadioisotopesCarbon-14

Autor:innen und Institutionen

  • Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
  • Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Sunshine Lake Pharma Co., Ltd., Guangdong, China.
  • Enterprise Key Laboratory of Anti-viral Drug Development, Guangdong, China.

ORCID-Profile: Chun-Yang Zhao, Jing-Ying Jia, Yan-Mei Liu

Zitieren

APA

Zhao, C., Liu, G., Qian, L., Zhuang, Y., Luo, L., Zhang, Y., Xie, H., Zhu, J., Li, M., Chen, Q., Liu, Y., Jia, J., & Liu, Y. (2026). Mass balance study of [ 14 C]Netanasvir Phosphate in healthy Chinese participants. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01655-25

Vancouver

Zhao C, Liu G, Qian L, Zhuang Y, Luo L, Zhang Y, et al. Mass balance study of [ 14 C]Netanasvir Phosphate in healthy Chinese participants. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01655-25

BibTeX
@article{Zhao2026,
  author = {Zhao, Chun-Yang and Liu, Gang-Yi and Qian, Lin and Zhuang, Yu-Lei and Luo, Lin and Zhang, Ying-Jun and Xie, Hong-Ming and Zhu, Jing and Li, Ming and Chen, Qian and Liu, Yun and Jia, Jing-Ying and Liu, Yan-Mei},
  title = {Mass balance study of [ 14 C]Netanasvir Phosphate in healthy Chinese participants},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {6},
  doi = {10.1128/aac.01655-25}
}
Kostenlos starten →